BACKGROUND/OBJECTIVES: Nutritional issues that are associated with Duchenne muscular dystrophy (DMD) remain poorly understood. The aim of this analysis was to describe and explore longitudinal observations of body mass index (BMI) in a cohort of children with DMD. SUBJECTS/METHODS: Anthropometric and clinical characteristics were collected retrospectively and longitudinally for boys with DMD seen in two large neuromuscular clinics. BMI Z-scores were determined using the Centers for Disease Control and Prevention reference values for children (2000). RESULTS: Medical records (n = 193) were examined from which 75% were included for analysis. The mean age of the cohort at the time of data collection was 11.9 years, with 72% of patients currently or previously using steroids. The highest prevalence of obesity based on the BMI Z-score was 50% at the age of 10 years. Longitudinally, BMI Z-scores from the age of 2 to 12 years plot approximately one s.d. above the mean, after which there is a marked and progressive decline. BMI gainers were identified for whom BMI Z-score increased by 1.65 units compared with the 0.09 units in non-gainers. BMI gainers were younger when they had their first BMI measurement (5.9 vs 7.2 years), and this measure was significantly lower compared with the non-gainers (BMI Z-score: 0.04 vs 1.17). In this cohort, BMI was associated with age, ambulatory status and lung function. CONCLUSIONS: This study demonstrates that boys with DMD using steroid therapy experience shifts in BMI. A declining BMI appears to be associated with increasing age. Interpretation of growth patterns is limited here by a lack of normative growth references in DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is the most common and severe muscular dystrophy of childhood. Affecting 1 in 3500 boys, the disease causes progressive and relentless muscle weakness, limiting life to the second or third decade. 1 Recently, there have been considerable developments in treatment for boys with DMD, particularly the near universal use of glucocorticosteroids (prednisone/prednisolone and deflazacourt), and the release of comprehensive clinical care recommendations. 1 Despite these recent advances, the nutritional issues associated with DMD are complex, are derived from a weak evidence base and remain poorly understood. 2 Boys with DMD can move from over-to under-nutrition within their shortened life span. In 1993, Willig first reported on the nutritional issues in a French cohort of 252 boys. 3 By 13 years of age, 54% of the cohort was obese (weight >90th percentile). Conversely, under-nutrition (weight o10th percentile) affected 54% of boys by the age of 18 years. In 1995, McDonald et al. 4 reported on an American cohort. Similarly, 44% of boys aged 9-13 years were >90th percentile in weight, whereas after the age of 17 years 65% weighed o 10th percentile. Data from a French cohort described in 2011 also suggests an increasing and maintained high prevalence of obesity. By 13 years of age, 73% of these participants were obese, whereas at 18 years of age 47% were obese and 34% were underweight. 5 All of these cited studies were conducted in steroid-naive cohorts.
The impact of long-term glucocorticosteroid therapy on both height and weight growth is significant and has not been sufficiently described in children with DMD. Although steroids are clearly beneficial for the maintenance of muscle strength and functional ability, side effects of treatment (such as excessive weight gain, impaired height growth, Cushingoid features, osteoporosis, hirtsutism, glucose intolerance, cataracts and behavioural changes) can be of sufficient concern to cause their withdrawal. [6] [7] [8] [9] Steroid therapy can also delay puberty, which in itself has repercussions for bone health and psychosocial wellbeing. 9, 10 This gamut of endocrinological issues is now the focus of much discussion. 9 Although the side effects of steroid therapy in DMD are widely recognised, there are still very little data on growth patterns in steroid-treated cohorts to inform the development of appropriate interventions and/or dietary guidelines. 2 Body mass index (BMI) is a useful clinical tool that is widely used to quickly assess weight status in relation to height, yet there have been no studies that document changes in BMI over time in DMD. Hence, the aim of this analysis was to describe BMI patterns in a cohort of boys with DMD using steroid therapy within the broader context of the clinical and physical characteristics of the group.
SUBJECTS AND METHODS
This retrospective cohort was derived from characteristics collected during routine clinic reviews of boys seen in two large Australian neuromuscular clinics: the Royal Children's Hospital, Melbourne, Victoria, Australia and MontroseAccess, Brisbane, Queensland, Australia. Each clinic is the major centre for specialist care of paediatric DMD in these states. Families are referred to these centres upon diagnosis; hence, this sample is expected to include the majority of boys with DMD in Queensland and Victoria, providing a combined population of 193 patients. Ethics approval was obtained from the Royal Children's Hospital, Melbourne (no.29075B) and the Royal Children's Hospital, Brisbane (HREC/09/QRCH/86). The project was supported by MontroseAccess, Brisbane.
Clinic lists were provided by coordinators at each centre, and corresponding medical histories were obtained. All available data were retrospectively collected: date of birth; age at diagnosis; ambulatory status and age at loss of ambulation; height (cm); body weight (kg); steroid use-type (prednisolone or deflazacort), dose, age at commencement; and lung function, forced expiratory volume in 1 s as a percentage of predicted and forced vital capacity as a percentage of predicted (FVC%). In these clinics, height and weight are routinely measured using standing scales and stadiometers. When boys are no longer able to stand, weight would typically be obtained using wheelchair scales and a hoist. From approximately 2005 onwards, height was estimated from ulna length. Before this, arm span was used to predict height. Subjects were excluded from analysis if the patient was subsequently deemed to have Becker muscular dystrophy; if a genetic report could not be located; or if there was inadequate clinical data within the medical history, that is, if there were no documented anthropometric measures.
From collected anthropometry data, BMI (weight (kg)/height (m) 2 ) was calculated. Weight, height and BMI Z-scores were determined using the Centers for Disease Control and Prevention (CDC) reference values for children from 2000. 11 For each subject, height and BMI measures were examined individually and grouped into year of age over the range of 2-17 years. Only one measure per subject was allocated within each year. Where several measures were available, the measure closest to mid-year was used. Within each year of age, BMI Z-scores were categorised as underweight (⩽5th percentile), appropriate weight (>5th and o 85th percentile), overweight (⩾85th and o95th percentile) and obese (⩾95th percentile) based on Australian definitions.
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Statistical analysis was conducted using SPSS, Version 18.0 (SPSS Inc., Chicago, IL, USA). Results are displayed as mean (s.d.) or median (interquartile range) for non-normally distributed variables. When comparing means, a two-sample Student's t-test or the non-parametric equivalent (Mann-Whitney U test) was used to detect differences between the groups. Multiple regression analysis was used to explore the relationship between clinical and genetic characteristics of boys with DMD. Standard multiple regression, in which all independent variables are entered into the equation simultaneously, was used. Before proceeding with the models, the following assumptions were examined: multicollinearity, normality and linearity, homoscedasticity and outliers. 13 For all analyses, significance was considered to be obtained when P ⩽ 0.05.
RESULTS
Data collection, which occurred between August and November 2009, examined a total of 193 medical records from which 144 (75%) were included for analysis. The majority of charts were excluded because there were no anthropometric measures documented. Eighty subjects (56%) were from Victoria and 64 (44%) were from Queensland, representing 92% and 60% of these clinic populations, respectively. Birth dates for participants included in the study fell between 1987 and 2005.
Clinical profile A clinical profile was completed using the most recent measure for clinical and anthropometric variables documented in each individual's medical chart, including information on steroid use ( Table 1) . The date at which measures were documented fell between 1997 and 2009.
Description of longitudinal changes in height
Longitudinal data for height is represented in Figure 1 . Between the ages of 2 and 13 years, height Z-scores fluctuate between − 0.5 and − 1.0 s.ds. below the mean. From ages 14 to 17 years, there is a marked decline in height Z-scores representing a slowing in height growth comparative with peers. Approximately one-third of height measures summarised in Figure 1 were estimated from a proxy measure (arm span or ulna length).
Description of longitudinal changes in BMI
Longitudinal data for BMI Z-score is presented in Figure 2 . BMI Z-scores hold steady at approximately 1 s.d. above the mean until the age of 12 years, after which there is a marked and progressive decline. The proportion of boys classified as underweight, appropriate weight, overweight and obese according to BMI percentile is summarised in Figure 3 for each age group. The decline in BMI Z-score with age is evident here; the proportion of patients with BMIo 5th percentile steadily increases with age. The highest prevalence of obesity based on BMI Z-score was 50% at the age of 10 years. The total BMI Z-score change over the period of documented history was calculated for each child by summing the BMI change between anthropometric data points. For the cohort, the median total BMI Z-score change was 0.38 (-0.27, 0.98) over a median period of 3.60 (2.45, 5.37) years.
The cohort was separated into those children who had/had not gained >1 Z-score unit in BMI within the review period (gainers/ non-gainers). Within a similar time frame, the gainers increased their BMI Z-score by 1.5 units compared with the non-gainers (Table 2) . However, the gainers were younger when they had their first BMI measurement, and this measure was significantly lower compared with the non-gainers.
Exploring the relationship between BMI Z-score and clinical factors Standard multiple linear regression was used to explore relationships between BMI Z-score and clinical factors (Table 3) . Clinical characteristics were entered into the model, which explained 32.5% of the variance in BMI Z-score (P o0.0005). BMI of boys with DMD was significantly associated with age (B = -0.386; explained 8.2% of variation in BMI Z-score), ambulatory status (B = 0.352; explained 6.0% of variation in BMI Z-score) and lung function (B = 0.426; explained 9.7% of variation in BMI Z-score). A lower BMI Z-score was associated with older age, and lower FVC. Although the relationship between BMI Z-score and ambulatory status was evident in this multivariate regression model, difference in BMI Z-score was not evident when boys who were ambulatory were directly compared with boys who could no longer walk (BMI Z-score: 1.19 ± 1.12 vs 0.50 ± 2.68, respectively, P = 0.700).
DISCUSSION
This analysis is unique. This is the first study to report height and BMI Z-scores based on CDC 2000 data in steroid-treated boys with 3, 14, 15 Although the aetiology of short stature in the absence of steroid treatment is unclear, it has been argued that it may provide some functional benefit owing to the 'favourable mechanics' associated with a smaller size. 9, 14 There is limited evidence suggesting that short stature may be associated with increased strength and improved clinical outcomes in boys with DMD. 4, 16 In the present cohort, mean height Z-scores decreased to less than − 1.0 s.d. below the mean between the ages of 14 and 17 years, at a time when boys should be reaching their adolescent growth spurt. This slowed growth may indicate growth failure secondary to chronic steroid use and delayed puberty, or it may reflect inaccurate estimation of body height owing to the presence of severe scoliosis and/or contractures in non-ambulatory boys. A decline in nutritional status could also be a contributing factor.
In this Australian cohort, the highest prevalence of obesity based on BMI percentiles was seen at the age of 10 years (50%). This is similar to the findings of McDonald et al. 4 and Willig et al.
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These are alarming statistics when compared with Australian population data; obesity affects 7% of boys aged 9-13 years using the same BMI percentile classification. 17 The proportion of boys found to be underweight during late adolescence was similar in the study by Martigne et al. 5 based on weight-for-age ratio and in this present study (based on BMI) (34% at age 18 years vs 27% at age 16 years, respectively). Other studies defining underweight as weight below the 10th percentile reported much higher proportions: 65% at the age of 17 years and 54% at the age of 18 years, respectively. 3, 4 The median total BMI Z-score change in the cohort was positive (0.38) over a median period of 3.60 years. Because BMI Z-score accounts for age and sex, if a child is tracking percentiles for height and weight his BMI Z-score should theoretically remain stable. A positive change in BMI Z-score indicates that weight growth is exceeding that of height growth, as expected in a steroid-treated cohort.
Multiple regression analysis was also used to explore the relationship between BMI and clinical factors in this cohort. BMI was associated with age, lung function and ambulatory status. A lower BMI Z-score was associated with older age and lower FVC. Earlier investigations have determined that FVC declines with age in a steroid-naive cohort. 15 In our cohort, it would seem that agerelated declines in lung function are also accompanied by declines in BMI. Owing to the observational nature of this study, we cannot determine whether declines in BMI are a contributing factor to or a symptom of declining lung function.
Comparisons of the BMI data presented here with examinations of weight patterns in other DMD cohorts are limited by the different classifications of overweight and underweight used and the absence of steroid treatment in the other cohorts. The need for standard classification systems for defining overweight and underweight across all studies is obvious, and it would allow for the clinical implications of over-and under-nutrition to be better explored. Furthermore, the use of BMI Z-scores based on CDC 2000 reference values establishes how boys with DMD grow comparative with peers who are unaffected. However, what we do not yet understand is 'normal' morphology for boys with DMD.
Classifying boys with DMD as overweight or underweight based solely on height and weight or BMI, without concurrent accurate Percentage of the cohort with more than one BMI measurement (n = 124). Bold is used to represent those variables for which there was a significant difference.
Exploring BMI in DMD ZE Davidson et al estimates of body composition, can also be problematic. Pessolano et al. 18 cautioned against using BMI for the evaluation of nutritional status in boys with DMD. The researchers determined that the number of boys classified as overweight using BMI only (n = 5) was much lower compared with the number of boys classified as overweight, using the percentage of expected weight for zero muscle mass from creatine excretion (n = 30). However, it is necessary to account for reduced stature in boys with DMD when assessing weight. As no other disease-specific index exists to classify weight for height, BMI remains a useful clinical tool if these limitations are acknowledged. Normative BMI data related to body composition within the dystrophinopathies would minimise such limitations.
This examination highlights the variability in body habitus in boys with DMD, which has also been identified anecdotally. 19, 20 Here, splitting the cohort based on BMI gainers and non-gainers revealed two very different groups. Closer inspection of the data would suggest that weight gain exceeds height growth at the beginning of childhood in DMD and that early identification of these growth patterns may be important for the prevention of severe obesity. This may be a crucial period for dietary intervention. Early identification of individuals with DMD who are at risk of both over-or under-nutrition would be of great benefit, because it would support the provision of anticipatory nutritional counselling. A recent retrospective multicentre audit provides some evidence for predicting patients at risk of undernutrition. 5 In this steroid-naive cohort, based on weight for age percentiles, obesity at the age of 13 years was associated with later obesity. Conversely, being normal weight or underweight at 13 years of age was associated with later underweight status. Although this study provides useful information on how to predict which boys will swing from overweight to underweight during their lifespan, one key question remains. How can we identify individuals who are likely to become overweight in childhood?
There are several limitations with this current study. Primarily, interpretation of the results is limited by the retrospective nature of the study, and thus causation should not be inferred from associations observed here. Inaccuracies in anthropometric measures, especially height, may have influenced findings. There was variability in how height was estimated for those boys who were unable to stand; either arm span or ulna length was used or in some instances it was unclear how height was estimated. This variability was due to new evidence to support the use of ulna length in boys, being published in 2004. 21 There is currently no gold-standard surrogate measure of height for young men with DMD. Until proxy height measures are validated in the DMD population, ulna length can be used routinely to predict height in the clinical setting. This measure has been shown to be reliable and valid in school-aged children and offers benefits above arm span in neuromuscular disorders where contractures may be present. 21 The use of BMI to document growth also has limitations. Although it is a useful clinical tool to document patterns of weight gain in relation to height, it cannot be used as an indication of nutritional status, especially in DMD where body composition is an important consideration. Again, owing to the retrospective and clinical nature of the study, we were unable to obtain information on other factors-such as body composition, biochemical indices or dietary intake-to build a sound nutritional profile of this cohort. In addition, we were unable to collect a standardised measure of motor function across the two clinics. Anecdotally, excessive weight gain is thought to be detrimental to motor function; however, there is little empirical evidence to support this. Prospective investigations, incorporating valid measures of body composition and motor function, are required to better understand the impact of growth on clinical outcomes in DMD and other neuromuscular conditions.
Finally, data were included from only 75% of medical charts reviewed mostly because of a lack of documented anthropometric measures in the remaining charts. The lack of anthropometric data in excluded charts and also the decreased frequency of observations towards late adolescence are likely due to the difficulty obtaining measurements from these patients if appropriate assistance and/or equipment were unavailable or if patients were too unwell for measurements to be taken. Therefore, the presented data may represent a 'best-case' scenario in which the full extremes of BMI are not captured. Routine growth monitoring should be included in standard clinical care for all boys with DMD to promote preventative nutritional guidance as opposed to reactive nutritional care. The lack of anthropometric data in almost one-quarter of charts reviewed highlights growth monitoring as an area of care that can be improved.
In summary, this study demonstrates that boys with DMD using steroid therapy experience shifts in BMI across their shortened lifespan. Weight gain appears to exceed gain in height in early childhood; this may be an important period for anticipatory guidance and nutrition counselling to prevent excessive weight gain. Conversely, a declining BMI appears to be associated with increasing years of age. Interpretation of growth patterns is limited here by a lack of normative growth references in DMD. Collection of prospective anthropometric data with clinical variables is warranted to provide a thorough understanding of the nutritional profile of DMD to support the development of appropriate and specific dietary guidelines. 
